Scope:
’Top 10 Global Pharmaceutical Companies Report: Strategic evaluation of industry and key players’ is a business report that provides a comprehensive view of the pharmaceutical industry and its top 10 companies.
The report includes the following:
– Industry analysis including market value, market volume, market share and forecast growth till 2012
– Assessment of intensity of competition based on five-forces model including degree of rivalry, substitutes, new entrants, buyer power and supplier power
– SWOT and 5-year financial analysis of top 10 players in the industry
– Descriptive profiles of the leading players including the strategic initiatives undertaken in the last 12 months
The top 10 companies have been ascertained based on their global revenues for the year ended 2007.
Highlights:
The global pharmaceutical market generated total revenues of $615.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-2008.
The cardiovascular segment was the market’s most lucrative in 2008, generating total revenues of $121.7 billion, equivalent to 19.8% of the market’s overall value.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 3.6% for the five-year period 2008-2013, which is expected to drive the market to a value of $734 billion by the end of 2013.
Reasons to Purchase
– Gain insights into the industry, leading companies and competitors through a single report
– Benchmark the leading players using 5-year financial analysis, ratios and adjusted financial statement data
– Form opinions about key players using SWOT Analysis to understand internal factors (strengths and weaknesses) and external factors (opportunities and threats) influencing the companies
– Determine industry attractiveness from five-forces analysis of constituent segments
Executive Summary 7
Industry analysis 7
Industry definition 7
Research highlights 7
Top 10 companies landscape 7
Market value 9
Market forecast 10
Market segmentation—product 11
Market segmentation—geographic 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Substitutes 17
Rivalry 18
Top 10 Companies Landscape 19
Overview 19
Revenue analysis 23
Financial performance analysis 24
Company Reports 29
Pfizer Inc 29
GlaxoSmithKline Plc 35
F. Hoffmann-La Roche 41
Novartis 46
Sanofi-Aventis 51
AstraZeneca 58
Abbott Laboratories 65
Merck & Co., Inc. 71
Wyeth 78
Bristol-Myers Squibb Company 83
Five Year Financial Information 89
Pfizer 89
GlaxoSmithKline 92
F. Hoffman-La Roche 95
Novartis 98
Sanofi-Aventis 101
AstraZeneca 104
Abbott Laboratories 107
Merck & Co. 110
Wyeth 113
Bristol-Myers Squibb Company 116
APPENDIX 119
FIGURES
Figure 1: Global pharmaceuticals market, $ billion, 2004–2008 9
Figure 2: Global pharmaceuticals market forecast, $ billion, 2008–2013 10
Figure 3: Global pharmaceuticals market segmentation—product, % share 2008* 11
Figure 4: Global pharmaceuticals market segmentation—geography, % share 2008* 12
Figure 5: Forces driving competition in the global pharmaceuticals market 13
Figure 6: Drivers of buyer power in the global pharmaceuticals market 14
Figure 7: Drivers of supplier power in the global pharmaceuticals market 15
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals market 16
Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals market 17
Figure 10: Drivers of degree of rivalry in the global pharmaceuticals market 18
Figure 11: Revenues of global top 10 pharmaceutical companies, $ million, FY2008 20
Figure 12: Revenue growth of global top 10 pharmaceutical companies, 2006–2008 24
Figure 13: Operating performance analysis, FY2008 25
Figure 14: Net profit analysis, FY2008 26
TABLES
Table 1: Global pharmaceutical market, $ billion, 2004–2008 9
Table 2: Global pharmaceuticals market forecast, $ billion, 2008–2013 10
Table 3: Global pharmaceuticals market segmentation—product , % share 2008* 11
Table 4: Global pharmaceuticals market segmentation—geography, % share 2008* 12
Table 5: Revenues of global top 10 pharmaceutical companies, $ million, FY2008 19
Table 6: Revenue growth of global top 10 pharmaceutical companies, 2006–2008 23
Table 7: Key financials of global top 10 pharmaceutical companies, FY2008 24
Table 8: Key industry specific ratios–FY2008 27
Table 9: Pfizer—Financial and operational highlights, 2004–2008 ($ million) 89
Table 10: Pfizer—Key industry specific ratios, 2004–2008 91
Table 11: GlaxoSmithKline—Financial and operational highlights, 2004–2008 ($ million) 92
Table 12: GlaxoSmithKline—Key industry specific ratios, 2004–2008 94
Table 13: F. Hoffman-La Roche—Financial and operational highlights, 2004–2008 ($ million) 95
Table 14: F. Hoffman-La Roche—Key industry specific ratios, 2004–2008 97
Table 15: Novartis—Financial and operational highlights, 2004–2008 ($ million) 98
Table 16: Novartis—Key industry specific ratios, 2004–2008 100
Table 17: Sanofi-Aventis—Financial and operational highlights, 2004–2008 ($ million) 101
Table 18: Sanofi-Aventis—Key industry specific ratios, 2004–2008 103
Table 19: AstraZeneca—Financial and operational highlights, 2004–2008 ($ million) 104
Table 20: AstraZeneca—Key industry specific ratios, 2004–2008 106
Table 21: Abbott Laboratories—Financial and operational highlights, 2004–2008 ($ million) 107
Table 22: Abbott Laboratories—Key industry specific ratios, 2004–2008 109
Table 23: Merck & Co.—Financial and operational highlights, 2004–2008 ($ million) 110
Table 24: Merck & Co.—Key industry specific ratios, 2004–2008 112
Table 25: Wyeth—Financial and operational highlights, 2004–2008 ($ million) 113
Table 26: Wyeth—Key industry specific ratios, 2004–2008 115
Table 27: Bristol-Myers Squibb Company—Financial and operational highlights, 2004–2008 ($ million) 116
Table 28: Bristol-Myers Squibb Company—Key industry specific ratios, 2004–2008 118
AstraZeneca
Bristol-Myers Squibb Company
F. Hoffmann-La Roche
GlaxoSmithKline Plc
Merck & Co.Inc.
Novartis
Pfizer Inc
Sanofi-Aventis
Wyeth
Other selected research from the 'Biotechnology' category:
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis
Biomarkers in Late Stage Clinical Trials: Applications, opportunities and activities of leading players
Other selected research from the 'Business Development' category:
Partneringdesk Ono Pharmaceutical Co., Ltd. and Company Deals Briefing
Deals and alliances in cardiovascular and circulatory diseases
Other selected research from the 'Finance & Investment' category:
Global Top 10 Healthcare Equipment Companies - Industry, Financial and SWOT Analysis
Biotech Exit Strategies: Delivering value to investors in a challenging funding market